User:Mr. Ibrahem/Selpercatinib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Selpercatinib
Clinical data
Trade namesRetevmo, Retsevmo
Other namesLOXO-292
AHFS/Drugs.comMonograph
MedlinePlusa620036
License data
Pregnancy
category
  • Avoid
Routes of
administration		By mouth
Drug classTyrosine kinase inhibitor
Legal status
Legal status
Identifiers
  • 6-(2-hydroxy-2-methylpropoxy)-4- (6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3- yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
Chemical and physical data
FormulaC29H31N7O3
Molar mass525.613 g·mol−1
3D model (JSmol)
  • CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O
  • InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3
  • Key:XIIOFHFUYBLOLW-UHFFFAOYSA-N

Selpercatinib, sold under the brand name Retevmo, is a medication used to treat certain types of non-small cell lung cancer and thyroid cancer.[3] It is used in cases that are either RET fusion positive or have a RET gene mutation.[3][1] It is used after other treatments have failed.[5] It is taken by mouth.[1]

Common side effects include liver problems, high blood sugar, dry mouth, diarrhea, kidney problems, tiredness, swelling, low platelets, and rash.[1] Other side effects may include high blood pressure, QT prolongation, bleeding, allergic reactions, and tumor lysis syndrome.[1] Use in pregnancy may harm the baby.[1] It is a kinase inhibitor, which blocks RET.[1]

Selpercatinib was approved for medical use in the United States in 2020 and Europe in 2021.[3][4] In the United States it costs about 258,000 USD per year as of 2021.[6] It has also bee approved in the United Kingdom.[5]

References[edit]

  1. ^ a b c d e f g h "Retevmo- selpercatinib capsule". DailyMed. Archived from the original on 4 March 2021. Retrieved 31 March 2021.
  2. ^ "Retsevmo EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 23 April 2021. Retrieved 23 April 2021.
  3. ^ a b c d "Selpercatinib Monograph for Professionals". Drugs.com. Archived from the original on 21 November 2021. Retrieved 12 October 2021.
  4. ^ a b "Retsevmo". Archived from the original on 23 April 2021. Retrieved 12 October 2021.
  5. ^ a b "Selpercatinib". SPS - Specialist Pharmacy Service. 14 February 2020. Archived from the original on 28 October 2020. Retrieved 12 October 2021.
  6. ^ "Retevmo Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 12 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Selpercatinib&oldid=1218851803"